A 35-year-old woman has a rare condition, NF-1 neurofibromatosis, that causes benign tumors to grow on her body. One of the ...

A presentation at the 2026 ONA Summit described the role of oncology nurses in managing the care of patients with NF-1 and PN undergoing treatment with MEK inhibitors.

Oral selumetinib (AstraZeneca) reduces tumor volume in children with inoperable plexiform neurofibroma, benign tumors of peripheral nerves related to neurofibromatosis type 1 (NF1), with acceptable ...

Neurofibromatosis type 1 (NF1) is a rare genetic condition that affects how certain nerve cells grow and develop. Children with NF1 can have small growths on or under the skin called neurofibromas.

This genetic condition causes tumors to form on nerves throughout the body, often showing up as skin changes. The right treatment and management approach can help address symptoms and potential ...

A genetic disease that causes tumors to form on nerves has a new FDA-approved treatment, a SpringWorks Therapeutics drug that can address a wider range of patients than the AstraZeneca product that ...

FDA approved SpringWorks' mirdametinib for NF1 patients with symptomatic plexiform neurofibromas, granting a priority review voucher. In the Phase 2b trial, Gomekli showed a 41% ORR in adults and 52% ...

Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV)MIAMI, April 20, ...

A rare genetic disorder known as Neurofibromatosis type one, or NF1, affects about one in 2,500 people in the U.S. That's about 120,000 people. Of those, half will develop a subtype--plexiform ...

Neurofibromatosis type 1 (NF1) is a genetic condition that affects the skin, nervous system, and other parts of the body. The condition, formerly called Von Recklinghausen disease, causes changes in ...

Treatment for neurofibromatosis type 1 may involve surgery, radiation, chemotherapy, or other methods. In some cases, doctors may take a “wait and see” approach. Neurofibromatosis type 1 (NF1), ...